Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05850234 · ClinicalTrials.gov registry record · Phase 1
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Relapsed Refractory Multiple Myeloma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT05850234 is a Phase 1 study of Relapsed Refractory Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 80 participants, below the 179-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05850234, a Phase 1 study of Relapsed Refractory Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Conditions Studied
Interventions
- BIOLOGICAL GC012F (AZD0120)
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
Florida
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Tampa
Colorado
- Research Site - Aurora
- Research Site - Denver
Massachusetts
- Research Site - Boston
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
- Research Site - Detroit
Minnesota
- Research Site - Minneapolis
- Research Site - Rochester
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05850234
The ClinicalTrials.gov registry entry for NCT05850234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (55% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which GC012F (AZD0120) is the first listed.
NCT05850234 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05850234 about?
NCT05850234 is a clinical study titled "A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma". This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
What is the current status of trial NCT05850234?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-07-20. Estimated completion is 2028-11-15.
What conditions does trial NCT05850234 study?
This clinical trial studies the following conditions: Relapsed Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05850234?
The interventions under investigation include: GC012F (AZD0120) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05850234?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05850234 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Myeloma-Developing Regimens Using Genomics (MyDRUG)
COMPLETED · Phase 1
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
-
ELISA in Relapsed/Refractory MM
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.